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Abstract 
Background: The respective place of endovascular versus open surgery in thoracic dissecting 
aneurysm treatment remains debatable. This comprehensive review seeks to analyse the 
outcomes of endovascular repair (ER) compared to open surgery (OS) in chronic type B 
aortic dissection treatment. 
Methods: Embase and Medline searches (2000 – 2017)were performed following Preferred 
Reporting Items for Systematic Review and Meta-Analyses guidelines. Outcomes data 
extracted comprised firstly early mortality and major complications: stroke, spinal cord 
ischemia (SCI), dialysis, respiratory complications; secondly, late survival and 
reinterventions. Reintervention causes were divided into proximal, adjacent, distal. 
Comparative studies provided comparative meta-analyses. Non-comparative studies were 
analysed in pooled proportion meta-analyses for each group. 
Results: 39 studies were identified: 10 OS, 25 ER, 4 comparative. Comparative studies meta-
analyses revealed lower early mortality for ER (OR: 4.13, 95% CI: 1.10 – 15.4), stroke (OR: 
4.33, 95% CI: 1.02-18.35), SCI (OR: 3.3, 95% CI: 0.97 – 11.25) and respiratory 
complications (OR: 6.88, 95% CI:1.52- 31.02), but higher reintervention rate (OR: 0.34, 95% 
CI: 0.16 – 0.69). Mid-term survival was similar (OR: 1.19, 95% CI:0.42 – 3.32). 
 Non-comparative studies analyses showed distal causes as the principal reintervention 
indication in both groups: OS 73%; ER 59%. Reintervention procedures were mainly surgical 
for OS (85%), mainly endovascular for ER (75%). Rupture rates were: OS 1.2% , ER 3%.  
Conclusions:  This recent non -randomised data shows early ER benefit, unsustained at mid-
term. Reintervention is higher after ER, necessitating improved technique. However, OS is 
exempt neither from reintervention nor rupture. Both techniques have their place, but patient 
selection is key.
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The question regarding optimal treatment of thoracic or thoracoabdominal aneurysms, whether 
degenerative or dissecting, still divides the surgical community (1). It has become more pertinent 
as the number of patients requiring repair during chronic phase of aortic dissection increases, due 
to improved imaging techniques, more sophisticated acute dissection management and better 
monitoring during follow-up. 
Open surgery (OS) has long been considered as standard treatment for chronic dissection where 
medical management has failed to prevent disease progression. It nevertheless remains that the 
anatomical specificities of dissecting aneurysms render open repair challengingly complex. This 
is reflected in the high operative risks incurred, as demonstrated by early series reporting 
operative mortality as high as 27% with serious neurological complication rates of up to 28% (2). 
These unfavourable outcomes, along with the emergence of endovascular treatment as a less 
invasive alternative for thoracic aneurysms, have prompted a gradual shift away from surgical 
repair.  
Endovascular repair (ER) for aortic dissection was first applied in acute phase, and favorable 
results lead to recommendations in an Interdisciplinary Expert Consensus Document that it 
should be considered as first-line treatment (3). Although the initial physiopathological 
mechanism is the same, chronic dissection is considered a different entity due to the fibrotic flap 
and multiple mature and stable communications between true and false lumen. These specific 
characteristics are responsible for a reputedly lower potential for remodelling, and consequently 
mid and long-term data have demonstrated higher reintervention rates (4). This has restricted the 
widespread acceptance of thoracic endovascular aortic repair (TEVAR) for this indication and 
accounts for reluctance to consider ER as a durable alternative to OS. 
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This study aims to offer a comprehensive analysis of current literature to determine early 
outcomes, mid or long-term survival and reintervention rates after chronic dissection repair by 
either open or endovascular intervention. 
 
Material and methods 
Literature search 
This review was conducted in accordance with the Preferred Reporting Items for Systematic 
Review and Meta-Analyses guidelines (5). To identify studies evaluating ER, OS, and those 
comparing the two techniques for chronic type B dissection treatment, an electronic search of 
Embase and Medline databases from 2000 to June 2017 was performed. The free-text search 
terms “aort*”, “dissection”, “type B”, “endovascular”, “repair”, “stent-graft”, “TEVAR”, 
“surgical treatment”, “open repair”, and the Medical Subheading term “dissection aneurysm” 
were used in combination with Boolean operators AND or OR. Additional hand-search was also 
undertaken in the Current Controlled Trials Register and Cochrane Database. 
Search was limited to English language studies. Inclusion criteria comprised: (1) randomised 
controlled trials and retrospective or prospective observational studies, (2) dated after 2000, (3) 
reporting at least 15 patients treated for chronic dissection, (4) either by open or endovascular 
repair, (5) providing sufficient data of early, mid or long-term outcomes. Exclusion criteria 
comprised: (1) arch or hybrid repair series, (2) reports with less than one-year follow-up, (3) 
mixed acute and chronic dissection series or degenerative and dissecting aneurysm series, where 
data regarding chronic patients or dissection could not be separated from the rest of the cohort, 
(4) randomised trials comparing TEVAR to medical treatment. 
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Definitions and endpoints 
- Chronic type B dissections were defined by a more than 2-week time frame following 
onset of symptoms and included any non-traumatic dissection. Data pooling from 
subacute and true chronic dissection was dictated by the limited number of publications 
adopting the categorization into acute, subacute and chronic. 
- Early mortality corresponded to death occurring either within 30 days of procedure or in 
hospital prior to discharge. 
- Endpoints were firstly, early mortality and major postoperative complications: stroke, 
spinal cord ischemia (SCI), de novo dialysis, respiratory complications; secondly, late 
survival and reinterventions. 
Aortic related reintervention comprised all aortic procedures occurring during follow-up, > 30-
days after index TEVAR, whether surgical or endovascular, and whether related to treated 
segment or at remote sites. Reinterventions unrelated to dissection were disregarded. Further 
details regarding indication type, treatment required and outcomes in terms of reintervention 
related mortality were also extracted. According to indication type, reintervention was divided 
into three subgroups: proximal, adjacent, distal to repair. For OS, proximal reintervention 
corresponded to proximal aneurysmal degeneration, type A dissection, proximal anastomotic 
pseudoaneurysm, whereas distal subgroup comprised distal aneurysmal degeneration. Graft 
infection, patch pseudoaneurysm, aortoesophageal fistula or visceral artery stenosis were 
categorized as adjacent subgroup. For ER, proximal subgroup encompassed retrograde 
dissection, type Ia endoleak and proximal extension. Distal reintervention was linked to distal 
aneurysmal degeneration. Type II or III endoleak, or other problems along the stented aorta, 
were considered as adjacent causes.  
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Data collection and analysis 
Data extracted from each study were related to patients and pathology on the one hand, and on 
the other, to early, mid or long-term outcomes (26 variables, see Appendix 1). Two authors 
independently identified and analysed eligible articles. Any discordance was discussed with a 
third reviewer. The variable “pathology extent” differed from “extent of repair” and was 
categorized according to Debakey classification: residual type I, types IIIa or IIIb.  When 
extension above or below coeliac axis was not specified, categorization was type III. Neither 
neurologic deficit < 72 hours nor temporary symptoms related to SCI, nor temporary dialysis 
were considered for calculation of major event rates. Respiratory complications encompassed 
various forms of pulmonary adverse events leading to prolonged ventilation. Survival data was 
obtained from at-risk scores tables or extracted from Kaplan Meier curves. Missing or lacking 
endpoint were not considered as nil. 
The Scottish Intercollegiate Guidelines Network tool was used for quality assessment (6). 
Statistical analysis 
 Comparative meta-analyses (ER vs OR) were performed for outcomes: hospital mortality, 
stroke, SCI, dialysis, respiratory complications, reintervention and mid-term survival. Survival 
rates were calculated at two time points (1 and 3 years). Pooled odds ratio (OR) with 95% 
confidence intervals (CIs) were calculated. Fixed or random effect was used according to 
heterogeneity degree which was examined by Cochrane’s Q statistic and I2 test. I2 value >50% 
indicated high heterogeneity and thus implies that the random effects model was used.   
Non-comparative studies referring to single treatment modality were not used for comparative 
meta-analysis but analysed separately in pooled proportion meta-analyses for each group. The 
latter data were presented as weighted frequencies or means with 95% CIs.  For primary 
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analysis, aggregated data from descending thoracic aorta (DTA), thoracoabdominal aorta (TAA) 
repair and  mixed DTA and TAA studies were presented. Sub-analysis within series targeting 
TAA repair was then performed. Exclusively DTA repair data were limited, precluding reliable 
statistical analysis. 
Funnel plot was used to evaluate publication bias. A two-sided p value < 0.05 was considered 
statistically significant. Statistical analysis was performed using Comprehensive Meta-Analysis 
Software version 2 (Biostat, New Jersey).  
Results 
Of the 1238 abstracts initially identified as potentially eligible, 39 studies met the inclusion and 
exclusion criteria and were selected to serve as the basis for the current review (Fig 1)(7- 45). 
Only 4 articles compared the two techniques.  Most studies were retrospective and based on 
single-centre experiences. There were 4 multi-centre studies, all of which reported on patients 
treated with TEVAR.  
 Data from non-comparative studies 
Pre- and intra-operative details 
10 studies reported 1079 patients treated with OS, mean age 58.1± 0.9 years. Overall, aortic 
dissection was mainly classified as Debakey IIIb (81.5%) and preoperative maximum aortic 
diameter was 63.5 ± 2.6 mm. The procedure was performed urgently or emergently in 14.4% of 
cases, most of which (89%) were due to rupture or impending rupture. Aorta replacement was 
extended to TAA in 63.2% of cases and limited to DTA in only 36.8 % (Appendix 2). 
TEVAR data stemmed from 25 studies totalling 1271 patients, mean age 59± 0.9 years. 
Dissection extent was Debakey IIIb in 79.6 % of patients and preoperative maximum aortic 
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diameter ranged from 52 to 76.8 mm, mean= 61± 1.8 mm. Urgent or emergent repair was 
required in 4.7% of cases, of which 52% were related to rupture or impending rupture 
(Appendix 2). Treatment consisted of standard TEVAR for all studies but two, which reported 
their experience with fenestrated or branched TEVAR. 
Early outcomes 
Cumulative all-cause early mortality was 9.3% (95% CI: 0.07 – 0.12) in OS group (table 1) and 
2% (95% CI: 0 – 0.03) in ER group (table 2). 
Cumulative stroke and SCI rates were respectively 4.5% (95% CI: 0.03 - 0.06) and 5% (95% CI: 
0.03 – 0.08) after OS, whereas in ER group stroke and SCI rates were 2.7% (95% CI: 0.017 - 
0.041) and 2.2% (95% CI: 0.014- 0.034). The overall need for dialysis was 5.2% (95% CI: 0.02 – 
0.11) after OS and 0% (95%: 0 – 0.01) after TEVAR.  
OS was associated with respiratory complications in 24.9% of cases (95% CI: 0.14- 0.39) 
compared to 4% (95% CI: 0.02 – 0.06) following TEVAR. 
Late survival 
In OS cohort, survival rates at 1 and 3 years were respectively 84% (95% CI: 0.78 - 0.88) and 
79.9% (95% CI: 0.71-0.86) (table 1). Only one study reported on aortic related mortality, which 
was 2.1% (table 3).  
In ER cohort, 1 and 3-year survival rates were similar: 91% (95% CI: 0.88- 0.95)(table 2). 
Aortic related death was mentioned in most studies,  with a 3.2%(95% CI: 0.02 - 0.04) 
cumulative rate (table 3), while all-cause late mortality was 9%. 
Reintervention, rupture and aortic remodelling 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 9 
For OS group, during an overall 65.5 months’ mean follow-up, reintervention was required in 
11.8 % of cases (95% CI: 0.08- 0.16), and rupture reported in only 3 studies, representing a 1.2% 
(95% CI: 0.005 - 0.032) cumulative rate (table 3).  
For ER group, mean follow-up time was 30.4± 2.8 months. Reintervention rate was 20.2% (95% 
CI: 0.15 – 0.26%), time to reintervention 15.4 months (range: 8.5- 23) and rupture rate 3% (95% 
CI: 0.02 – 0.04) (table 3).  
Indications for reintervention and its treatments for both groups are listed in table 3.  
After OS, causes for reintervention were considerably more frequent distal to the treated segment 
(73%) than adjacent (16.7%) or proximal (10.5%). Similarly for ER the main causes leading to 
reintervention were distal (59%), followed by proximal (32%) and adjacent to stent-graft (9%). 
For OS, reintervention procedures were mainly surgical (85%), while for ER they were 
endovascular (75%). Outcomes data after secondary intervention were described only in TEVAR 
studies, with reintervention related mortality rate of 1.4% (95% CI: 0.008 – 0.026).  
After ER, aortic remodelling was assessed at various anatomic levels and according to different 
morphological parameters (Appendix 2). Cumulative complete thoracic aorta thrombosis was 
71.7% (95% CI: 0.57- 0.82).  Association between survival and remodelling was analysed by 2 
studies: contrary to Scali et al (35), Mani et al (33) observed positive effect on mid-term-
survival,  
Data from comparative studies 
Pre- and intra-operative details 
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Four studies involving 195 patients treated with  OS and 139 with ER contributed to meta-
analysis. Comparison of demographic characteristics showed that patients receiving ER were 
older than those receiving OS (64.3 ± 2 years vs 58± 2 years, p= 0.01) with more frequent 
coronary artery disease, chronic obstructive pulmonary disease and renal failure, yet the 
differences were not statistically significant (18.2% vs 16.2%, p=0.742; 25.4% vs 14.7%, 
p=0.284; 19.3% vs 13.3%, p=0.575). Dissection was more likely to be associated with 
connective tissue disorder in OS: 17.6% vs 2% (p= 0.002). The proportion of procedures 
performed in urgent or emergent setting was similar between the 2 groups (19.2% for OS vs 
27.9% for ER, p= 0.55). Mean time from dissection to index intervention was higher for OS 
(30.9± 10.4 vs 22.1± 10.4 months, p=0.55). Anatomic characteristics comparison revealed that 
dissection was more commonly extensive in OS ( Debakey IIIb 80.2% in OS versus 60.7% in 
ER, p=0.30) with larger maximum aortic diameter (63 ± 4 mm vs 55.8 ± 3 mm, p= 0.15). Repair 
extent was limited to DTA in 97.7 % of cases in ER and, on the contrary, extended to TAA in 
72.4% of cases in OS (p=0.001). 
Early outcomes 
Cumulative all-cause early mortality was significantly lower in ER versus OS (OR: 4.13, 95% 
CI: 1.10 – 15.4, p=0.035) (Fig 2A). Adverse neurologic events were significantly higher after OS 
for overall risk of stroke and SCI, respectively (OR: 4.33, 95% CI: 1.02-18.35, p=0.04) and (OR: 
3.3, 95% CI: 0.97 – 11.25, p=0.05) (Fig 2B, 2C). Following OS, patients were more likely to 
develop severe respiratory complications (OR: 6.88, 95% CI:1.52- 31.02 , p=0.01)(Fig 2D). 
Surprisingly the need for permanent dialysis in postoperative course did not significantly differ 
between ER and OS (OR: 2.99, 95% CI: 0.56 - 15.97, p=0.20) (Fig 3A). 
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Late survival 
Survival analysis at 1 and 3 years showed no benefit of one technique over the other: (OR: 0.73, 
95% CI: 0.34 – 1.55, p=0.41) and (OR: 1.19, 95% CI: 0.42 – 3.32, p= 0.73) (Fig 3B,3C). Funnel 
plots did not indicate a significant risk of bias for mortality outcome. 
Reintervention and rupture 
Compared to OS, endovascular repair significantly increased reintervention risk (OR: 0.34, 95% 
CI: 0.16 – 0.69, p=0.003) (Fig 3D). There was no difference between OS and ER in terms of 
indication type, whether proximal (p=0.81), adjacent (p=0.06) or distal (p=0.27) to the treated 
segment. However reintervention was more often managed using endovascular techniques in ER 
group (OR: 0.24, 95% CI: 0.08 – 0.69, p=0.008). Reintervention related mortality was noted in 
only 2 studies and did not significantly differ between OS and ER (OR: 0.49, 95% CI: 0.10 – 
2.46, p=0.39). 
Since details about rupture were not provided in the OS group, comparative meta-analysis was 
impossible for this outcome. 
Thoracoabdominal aneurysmal dissection repair 
Five studies reported data on TAA repair: OS cohort =160 patients; ER cohort = 63 patients. 
Early outcomes 
Cumulative all-cause early mortality was 7.5% (95% CI: 0.04 – 0.13) in OS group and 8.9 % 
(95% CI: 0.02 – 0.26) in ER. 
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Cumulative stroke and SCI rates were respectively 3.9% (95% CI: 0.02 – 0.08) and 9.2% (95% 
CI:0.05 – 0.15) after OS, whereas for ER cumulative SCI rate was 0%. Stroke rate was provided 
by only one study: 0% (Appendix 3). 
Late survival 
One- year survival was 86.6% (95% CI: 0.80 – 0.91) and 87.5% (95% CI: 0.71- 0.95) 
respectively for OS and ER cohorts. Three-year survival was provided by only one study: 75% 
for OS and 85% for ER. 
Reintervention 
Reintervention rates were 14.7% (95% CI:0.03 – 0.44) for OS and 34 % (95% CI:0.09 – 0.72) 
for ER. 
Comment 
Given the advances in imaging, surgical techniques, critical care and knowledge of aortic 
dissection in the last decades, and to avoid bias related to the use of historical series, this 
comprehensive review search was limited to concurrent series. In contemporary literature 
surgical series are considerably less plentiful than endovascular. This may be partly explained by 
the fact that such complex aortic surgery is limited to high- volume centers, whereas TEVAR can 
be performed in less restrictive environments. The higher median of patients in surgical (n=79) 
compared to endovascular series (n=40) supports this observation. It must nevertheless be noted 
that, beyond simple stent-graft deployment in diseased aorta, appropriate TEVAR for aortic 
dissection is challenging. Technical success requires preliminary fine-tune imaging analysis with 
exact anatomical characterization, notably intimo-medial tear location; high endovascular skill 
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level to overcome procedural pitfalls; accumulated experience permitting adapted algorithmic 
approach. 
One concern raised by some authors is that comparison between open and endovascular repair is 
difficult because of differing patient populations (9, 42), and this was indeed the case in our 
comparative studies cohort. Similar maximum aortic diameter noted in both groups, indirectly 
indicates that the reputedly less invasive nature of endovascular approach has not led to a size 
threshold lowering. 
Despite the fact that pathology extended to TAA in most cases in both groups, repair extent 
differed, with more need to involve TAA in OS group. This can be explained by the two 
different treatment principles. OS is based on replacement of aneurysmal aortic segment, but, to 
successfully perform distal anastomosis, this segment must be relatively healthy, yet is not 
always readily available within thoracic aorta. On the other hand, TEVAR aims to seal the entry 
tear and achieve false lumen thrombus with less concern about distal landing zone. This 
difference could be a potential confounding factor to be considered when interpreting results, and 
could explain the higher mortality and morbidity rates noted in OS cohort.  
This review provides evidence of the early mortality and morbidity benefit of TEVAR: lower all-
cause hospital mortality, lower stroke and SCI rates.  In comparison to what has been reported in 
OS literature in the last 20 years, the rate of major complications is undoubtedly lower in the 
present review, yet remains higher compared to ER.  
The higher rate of permanent neurological events after OS generates functionality and autonomy 
loss, thus reducing life quality. No comparative study objectively documented this. Despite wide 
use of protective techniques, such as spinal fluid drainage in both types of intervention, SCI still 
remains more of an issue for surgical repair. 
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Endovascular sceptics often cite the more frequent need for reintervention associated with ER in 
mid or long term. Even if effectively more frequent after ER, this review showed that OS was 
not exempt from reintervention risk. Indeed, in open group, the rate was as high as 12% with 
over half to treat distal expansion of dissected aorta, even though distal anastomosis is usually 
performed in apparently healthy aorta. Pujara et al (10) found maximum aortic diameter, as well 
as diameter at diaphragm or renal artery levels, as predictive of poor late outcomes in terms of 
death and reintervention after OS.  
Similarly, after TEVAR, causes distal to stent-graft accounted for about 60% of reinterventions, 
in line with recent systematic review report (46). The latter identified aneurysmal dilatation of 
distal aorta secondary to retrograde false lumen perfusion as the most common reason for 
reintervention. This probably implies that some kind of reintervention is unavoidable because 
inherent to the pathology itself, and not to the technique, whether surgical or endovascular. 
While reintervention is certainly frequent after TEVAR, it can mostly be treated by endovascular 
means, and related mortality was similar in both repair groups.  
Secondary rupture rates were very low for both techniques. Proponents of OS advocate that once 
dissected segment is eliminated, risk of secondary rupture is nil (16). This review reveals that 
even if rupture rate is lower after OS, it still occurs. Additionally, this cumulative rupture rate 
may be underestimated since numerous surgical studies failed to expressly mention this 
complication.  
This study  indicates that mid-term survival after ER is no better than after OS, a result which 
should be interpreted cautiously, since, of the 25 studies reviewed, only 15 reported on 3-year 
survival. The decline of initial ER survival benefit could be attributed to higher aortic related 
death secondary to reintervention and/or to increased cardiopulmonary death unrelated to 
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dissection. The fact that ER patients were more frail with more advanced atherosclerosis, a 
tendency reflected in preoperative demographic characteristics, argues in favour of the second 
hypothesis, as does the absence of difference in reintervention related mortality found in the 
comparative studies. Goodney et al (47) reached a similar conclusion to explain unsustained ER 
mid or long-term survival benefit after degenerative aneurysm repair. Moreover, the fact that 
chronic phase is less likely to promote aortic remodelling may account for this finding. Indeed 
authors postulate that FL patency is indicative of poorer survival (32, 33). However, data in this 
meta-analysis was not conclusive since only 2 studies analysed association between remodelling 
and survival, and reported contradictory results 
Endovascular device progress, in particular fenestrated and branched stent-graft availability, now 
enables more extensive dissecting aneurysm treatment. Surprisingly, this review showed similar 
hospital mortality and 1-year survival rates in both groups. Greenberg et al’s comparative study 
mixing degenerative and dissecting aneurysm reported analogous results. However, a 2-year 
survival benefit was noted  for ER(48). 
Limitations 
A significant limitation stems from existing data, which, in most OS studies, combined DTA and 
TAA repair, whereas, with the exception of two series, ER studies reported only on DTA repair, 
which may have biased outcomes in favor of ER. This difference is however inevitable and 
inherent to the principles of each technique, and cannot therefore be considered as heterogeneity 
of available data. For this reason a subanalysis focussed on TAA repair was provided in this 
review. These TAA cohort results should however be interpreted with caution, given the limited 
existing reports. Other differences in patient populations between ER and OS were detected and 
may have been a source of bias.  
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Another limitation in the comparative meta-analyses is inherent to the small populations treated 
and to bias related to ER or OS patient-selection based on anatomy and clinical status. However, 
if ever such bias occurred, it would have favored TEVAR for anatomical suitability and OS for 
clinical status, since better outcomes are expected in younger and fitter patients.  
Furthermore, major event rates are probably underestimated for both techniques, since neither 
temporary dialysis nor temporary neurological complications were considered.  
Finally, neither OS nor ER was compared to hybrid repair, which remains an accepted treatment 
modality. These hybrid series were excluded given the mixed population treated. 
Conclusion 
Available surgical and endovascular chronic dissection treatment guidelines are based on 
retrospective studies, and well-conducted prospective trials comparing the two techniques are 
lacking. Optimal management of complicated chronic dissection still needs to be precisely 
defined and no firm recommendation favoring either technique can be advanced. 
Nevertheless, compared with OS, this study shows that ER had better early outcomes, although 
this benefit was not sustained for mid-term survival. Assumption that reintervention is a major 
problem after ER may be unfounded, as survival seemed unaffected and secondary rupture rare. 
Conversely, during OS, diseased aorta resection does not completely eliminate either 
reintervention risk or rupture, especially regarding dilatation of distal untreated segment. Both 
techniques undoubtedly have their place, but patient selection is key.  
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Author/study and 
year 
All-cause early 
mortality 
n(%) 
Stroke 
 n (%) 
 SCI 
n (%) 
Definitive 
dialysis 
n (%) 
Respiratory 
complications n 
(%) 
 
Survival (%) 
Quality 
assessment 
1-year 3-year  
Miyamoto 2008 0 2 (5) 0   - 5 (12.5) 96 94 ++ 
Mutsuga 2010 0  2 (6.1) 3 (9.1)  - 8 (24.3)  - - + 
Zoli 2010 10 (9.6) 6 (5.8) 5 (4.8) 1 (0.9) 16 (15.4) 78 75 +++ 
Conrad 2011 8 (11) 2 (3) 12 (16.4)  - 36 (49) 72 64 ++ 
Pujara 2012 16 (9.4) 8 (4.7) 4 (2.4) 10 (5.9) 22 (13)  - - +++ 
Bashir 2014 14 (22.6) 7 (11.3) 2 (3.2) 16 (15.8)  - 76 73 ++ 
Conway 2014 5 (5.8) 2 (2.3) 3 (3.4) 2 (2.3) 53 (62) 97 88.4 ++ 
Estera 2015 18 (8.6) 5 (2.4) 5 (2.4) 11 (5.2)  - 83 - +++ 
Fujikawa 2015 20 (8.5) 7 (3) 14 (5.9) 9 (3.8) 78 (33.3) 87.6 86.5 ++ 
Kouchoukos 2015 4 (5.8) 2 (3) 4 (6.1) 3 (4.5) 7 (10.6) 86.6 75 ++ 
Cumulative 
data(weighted 
average) 
95/1079 
 9.3%  
43/1079 
 4.5%  
52/1079  
5%  
52/929 
5.2% 
225/808  
24.9%  
84%  79.9%  
Table 1: Early outcomes and late survival after open surgery 
Data are n (%) or % 
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SCI = spinal cord ischemia 
- = not reported 
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Author/study and year All-cause 
early mortality 
n (%) 
Stroke 
 n (%) 
 SCI 
n (%) 
Definitive 
dialysis 
n (%) 
Respiratory 
complications 
n (%) 
Survival % Quality 
assessment 
1-year 3-year  
Kusagawa 2005 0 - - - - 100 100 + 
Eggebrecht 2005 0 0 0 - - 86.4 78.8 + 
Bockler 2006 0 0 0 0 - 100 - + 
Song 2006 2 (11.8) 1 (5.9) 0 - - - - + 
Jing 2008 0 0 0 - - - - + 
Sayer 2008 3 (7.5) 0 0 - - 80 66.5 ++ 
Alves 2009 2 (3.3) - - - - - - ++ 
Guangqi 2009 4 (8.2) 1 (2) 0  0  4 (8) 82.9 64.7 ++ 
Kim 2009 0  0 0 0 - - - ++ 
Xu 2010 1 (1.2) 0 0 - - 93 90 ++ 
Parsa 2011 0 0 0 1 (2) - 86.7 77.7 ++ 
Kang 2011 4 (5) 1 (1.3) 0 0 7 (9.2) 86 80 ++ 
Oberhuber 2011 0 0 1 (5.2) 0 - - - + 
Andachech 2012 10 (14) 1 (1.3) 1 (1.3) 0 - 81 - ++ 
Yang 2012 2 (7.1) 1 (3.6) 0 1 (3.6) 3 (10.7) 89 89 ++ 
Qing 2012 0 0 1 (3) - - - - + 
Mani 2012 3 (5.1) 0 0 - 2 (3.4) 89 64 ++ 
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Jia 2013 0 0 2 (0.9) - - 95 82.7 +++ 
Scali 2013 2 (2.5) 6 (7.5) 5 (6.2) - 3 (4) 89 80 ++ 
Lee 2013 1 (1.4) 0 0 - - 97.1 88.9 ++ 
Kitagawa 2013 0 0 0 0 0 85 85 + 
Song 2014 0 0 0 0 0 - - + 
Virtue registry 2014 0 0 1 (2) - - - 86 ++ 
Kitamura 2014 0 2 (3.8) 0 1 (1.8) 1 (1.2) 100 90 +++ 
Oikonomou 2014 2 (11.8) - 0 1 (5.9) - 88.2 - + 
Cumulative 
data(weighted 
average) 
36/1271 
2%   
13/1176 
2.7% 
 
11/1193 
2.2%  
4/490 
0%  
20/379 
4%  
91%   91%   
 
Table 2: Early outcomes and late survival after endovascular repair 
Data are n (%) or % 
SCI = spinal cord ischemia 
- = not reported 
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Author/stud
y  
Follow-
up 
(month
s) 
Reinterv
ention 
delay 
(months) 
Reinterventi
on n (%) 
Indication of reintervention Reintervention type Rupture 
n (%) 
Aorta 
related late 
mortality 
n(%) 
Reinterv
ention 
related 
mortality 
n(%) 
proximal adjacen
t 
distal Endovas
cular  
surgical hybrid 
Open repair 
Miyamoto  117±56
.4 
128 ±103 3(7.5%) 0 0 3(100) 0 3(100) 0 - - - 
Mutsuga  - - - - - - - - - - - - 
Zoli  68.4 
±54 
68.4±34.
8 
9 (8.6) 0 0 9(100) 0 9(100) 0 - - - 
Conrad  53± 
61.8 
- - - - - - - - - - - 
Pujara  23±15.
6 
- 23 (14) 14*(35) 12*(30) 14*(35) 22(55) 18 (45) 0 1 (0.6) - - 
Bashir  43.2±4
4.6 
- - - - - - - - - - - 
Conway  55.2±1
3.9 
Median 
51.6 
5 (5.8) 0 1(20) 4(80) 0 5(100) 0 - - - 
Estera  102±44
.6 
41.6±39 19 (9) - - - 0 19(100) 0 - - - 
Fujikawa  - - 31 (13.2) 5(16.2) 7(22.5) 19(61.3) 10(32.3) 21(67.7) 0 1 (0.4) 5(2.1) - 
Kouchouko
s  
64.8±6
6 
- 18 (26) 6*(30) 10*(50) 4*(20) - - - 2 (2.9) - - 
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Cumulative 
data(weigh
ted 
average) 
65.5±1
1 
65±9 108/911 
11.8% 
25/108 
10.5% 
30/108
16.7% 
53/108 
73% 
32/107 
15 % 
75/107 
85% 
0% 4/472 
1.2%  
- - 
Endovascular repair 
Kusagawa  43.2±1
8 
- 0 0 0 0 0 0 0 0 0 0 
Eggebrecht  18(1- 
55) 
- - - - - - - - 3(9) - - 
Bockler  24 - 4(23.5) 1(25) 0 3(75) - - - 1(5.8) 2(11.7) 0 
Song  11 - 2(12) 0 0 2(100) 2(100) - - 0 0 0 
Jing  17±14 - - -  - - - -  - 0 - - 
Sayer  - - 14(35) 3(21.4) 1(0.7) 10(71.4) - - - 0 - - 
Alves  36±28.
5 
- 13(22) - - - - - - - - - 
Guangqi  22.1±2
0.8 
- - - - - - - - 0 0 - 
Kim  64.4 
±38.8 
- 9(12.5) 1(11.1) 0 8(88.9) 7(77.8) 2(22.2) 0 1(1.4) 1(1.4) 0 
Xu  33.2±1
9.2 
- 5(6) 4(80) 0 1(20) 4(80) 1(20) 0 4(4.7) 4(4.7) 0 
Parsa  27±16.
5 
- 11(21.5) 4(36.4) 3(27.2) 4(36.4) 9(81.8) 2(18.2) 0 - 1(1.9) 1(1.9) 
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Kang 33.5 ± 
29.4 
15±16.7 17(22) 5*(29.4) 1*(5.9) 12*(70.6
) 
9*(50) 9*(50) 0 1(1.3) 1(1.3) 0 
Oberhuber  13(1-
124) 
23(6-59) 9(47.3) - - - 7(77.8) 2(22.2) 0 - 0 0 
Andachech  Mean 
18 
- 11(15) 7(63.6) 0 4(36.4) 9(81.8) 0 2(18.2
) 
0 0 0 
Yang  26.1±1
7.8 
- 4(10.7) 1(25) 0 3(75) 3(75) 1(25) 0 0 1(3.6) 1(3.6) 
Qing  31.7±1
7 
34 2(6.2) 1(50) 0 1(50) 1(50) 1(50) 0 0 0 0 
Mani 38±28 15±18 12(25.5) 3*(17.6) 3*(17.6
) 
11*(64.7
) 
5*(29.4) 12*(70.6) 0 1(1.7) 2(3.4) 1(1.7) 
Jia  28.5±1
6.3 
- 9(4) 3(33.3) 0 6(66.7) 6(66.7) 3(33.3) 0 6(2.9) 6(2.9) 1(0.4) 
Scali  24±21.
4 
17(4-33) 23(29) - - - 16*(55.2
) 
13*(44.8) 0 0 - 0 
Lee  - - 25(35.2) 13*(46.4) 2*(7.1) 13*(46.4) 12*(42.8) 15*(53.6) 1*(3.6
) 
2(3) 2(3) 0 
Kitagawa  20.4±1
8 
- 8(53.3) - - - 8(100) 0 0 - 1(6.7) - 
Song 10.3± 5 8.5±4.9 2(10) 0 0 2(100) 2(100) 0 0 0 0 0 
Virtue 
registry  
- - 14(28) 4(28.6) 2(14.3) 8(57.1) 12(85.7) 1(7.1) 1(7.1) 1(2) 2(4) - 
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Kitamura  90±46 - 21(40) - - - - - - 2(3.7) - - 
Oikonomou  12(4-
28) 
- 3(17.6) 0 2(66.7) 1(33.3) - - - - 0 0 
Cumulative 
data(weigh
ted 
average) 
30.4±2.
8 
15.4 ±2.3 218/1159 
20.2% 
50/153 
32% 
14/153
9% 
89/153 
59% 
110/176 
75% 
62/176 
16% 
4/176
9% 
22/1108 
3% 
29/974 
3.2% 
4/940 
1.4% 
 
Table 3: Late outcomes data after open surgery and endovascular repair 
Data are n (%)  
- = not reported 
* number of procedures 
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Figure Legends 
 
Fig 1: Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow chart 
Fig 2: (A) Random-effect meta-analysis plot for all cause early mortality comparing 
endovascular repair (ER) and open surgery (OS); CI= confidence interval (B) Random-effect 
meta-analysis plot for stroke comparing endovascular repair (ER) and open surgery (OS); CI= 
confidence interval (C) Random-effect meta-analysis plot for spinal cord ischemia comparing 
endovascular repair (ER) and open surgery (OS); CI= confidence interval (D) Random-effect 
meta-analysis plot for respiratory complications comparing endovascular repair (ER) and open 
surgery (OS); CI= confidence interval 
Fig 3: (A) Random-effect meta-analysis plot for dialysis comparing endovascular repair (ER) 
and open surgery (OS); CI= confidence interval (B) Random-effect meta-analysis plot for 1-year 
survival comparing endovascular repair (ER) and open surgery (OS); CI= confidence interval (C) 
Random-effect meta-analysis plot for 3-years survival comparing endovascular repair (ER) and 
open surgery (OS); CI= confidence interval (D) Random-effect meta-analysis plot for 
reintervention comparing endovascular repair (ER) and open surgery (OS); CI= confidence 
interval 
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